Women's health diagnostics have witnessed significant advancements in recent years, offering specialized applications and numerous advantages. Advanced imaging technologies like 3D mammography and ultrasound enable early detection of breast cancer and other reproductive health issues. Non-invasive prenatal testing ensures safer pregnancy monitoring. Genetic testing identifies hereditary risks, allowing tailored treatment plans. Digital health platforms offer remote monitoring and personalized care. These innovations provide accurate diagnoses, timely interventions, and improved outcomes for women's health concerns. Ultimately, women's health diagnostics contribute to proactive healthcare, promoting overall well-being and empowering women to make informed decisions about their health.
According to Data Bridge Market Research, the U.S. Women’s Health Diagnostics Market accounted at USD 5,962.00 million in 2023 and is expected to reach USD 11,462.00 million by 2030. The market is expected to grow with a CAGR of 8.5% in the forecast period of 2023 to 2030.
“Notable shift towards preventive healthcare boosts the market’s growth”
The women's health diagnostics market is experiencing growth due to a notable shift towards preventive healthcare. Increasing awareness among women about the importance of early detection and regular health screenings has increased the demand for diagnostic tests and services. Preventive healthcare initiatives and advancements in diagnostic technologies offer better and more accessible options for women's health screenings. This shift towards proactive healthcare practices is driving the market's expansion as more women prioritize their well-being and seek timely diagnostic solutions.
What restraints the growth of the U.S. Women’s Health Diagnostics Market?
“High cost of diagnostic procedures restraints the market’s growth”
The high cost of diagnostic procedures hinders the growth of the women's health diagnostics market. Expensive diagnostic tests and services may limit access for some women, particularly those with limited financial resources or inadequate healthcare coverage. The affordability barrier can deter women from seeking essential screenings and early detection, leading to delayed diagnoses and potential health risks, thus restraining the market’s growth.
Segmentation: U.S. Women’s Health Diagnostics Market
The U.S. Women’s health diagnostics market is segmented on the basis of diagnostic devices, application, and end user.
- On the basis of diagnostic devices, the Women’s health diagnostics market has been segmented into imaging and monitoring systems, Biopsy Devices, reagents and kits, biomarkers and others.
- On the basis of application, the Women’s health diagnostics market has been segmented into osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy and fertility testing, prenatal genetic screening and carrier testing, infectious disease testing, STD testing and ultrasound tests.
- On the basis of end user, the Women’s health diagnostics market has been segmented into hospitals, diagnostic and imaging centres, clinics and home care setting.
To know more about the study visit, https://www.databridgemarketresearch.com/de/reports/us-womens-health-diagnostics-market
Recent Developments
- In April 2023, Quest Diagnostics and NewYork-Presbyterian successfully concluded the acquisition of select assets from the laboratory services business of NewYork-Presbyterian. This collaboration aims to offer providers and patients access to a comprehensive service menu that leverages the combined strengths of both organizations.
- In March 2023, F. Hoffmann-La Roche Ltd revealed a collaboration with Eli Lilly and Company to assist in developing Roche's Elecsys Amyloid Plasma Panel (EAPP). This novel blood test is designed to enable earlier detection of Alzheimer's disease, offering potential benefits in diagnosing the condition at an earlier stage.
The Prominent Key Players Operating in the U.S. Women’s Health Diagnostics Market Include:
- bioMérieux SA (France)
- Carestream Health (U.S.)
- MEDGYN PRODUCTS, INC. (U.S.)
- COOK (U.S.)
- Cardinal Health (U.S.)
- PerkinElmer Inc. (U.S.)
- GENERAL ELECTRIC (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Sysmex Corporation (Japan)
- Siemens (Germany)
- Hologic Inc. (U.S.)
- Abbott (U.S.)
- BD (Becton, Dickinson, and Company) (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- NeuroLogica Corp. (U.S.)
- Danaher (U.S.)
- FUJIFILM Holdings Corporation (Japan)
- Hitachi, Ltd. (Japan)
- Canon Inc. (Japan)
Above are the key players covered in the report, to know about more and exhaustive list of U.S. women’s health diagnostics market companies contact, https://www.databridgemarketresearch.com/de/contact
Research Methodology: U.S. Women’s Health Diagnostics Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, U.S. vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
